IPF COMFORT Study for Chronic Cough
Trial Objectives
The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis. The investigational drug the study is testing is a once a day tablet called orvepitant. The cough in IPF may be caused by the airways becoming oversensitive, and it is hoped that orvepitant will reduce this over-sensitivity.
The purpose of the IPF COMFORT Study is to see if orvepitant reduces the severity and burden of coughing in people with IPF. The study will also test the safety of orvepitant, how the drug is absorbed and used within the body. Orvepitant is an investigational medicine. This means that it is not approved for sale, but it is but it is approved for use in clinical studies like this one.
Who Can Participate
People ages 40 and older who have been diagnosed with Idiopathic Pulmonary Fibrosis and have had a troublesome cough lasting for at least 8 weeks that has not responded to other treatments
Age: 40+ Gender: Any
Estimated Time Commitment
Six study appointments over 17 weeks, with clinic visits every three to four weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
NeRRe Therapeutics Ltd
Principal Investigators
Jeff Swigris, DO, MS